肺动静脉瘘患者的缺血性卒中
肺动静脉瘘患者较无肺动静脉瘘者更年轻、住院致残率和病死率更低,但未接受机械取栓。
要点
- 肺动静脉瘘是急性缺血性卒中的可治疗病因,当前指南未提及。
- 肺动静脉瘘相关卒中患者更年轻,住院致残率和病死率更低。
- 低氧血症、肺出血、肺高血压等是肺动静脉瘘患者发生卒中的独立风险标志。
核心结论
- 肺动静脉瘘相关缺血性卒中代表较年轻人群,具有独特的卒中风险标志,包括可治疗的肺动静脉瘘和缺铁性贫血。
主要发现
- 822例(0.02%)诊断为肺动静脉瘘,其中106例(12.9%)诊断为遗传性出血性毛细血管扩张症。
- 肺动静脉瘘患病率从2005年每百万卒中住院197例升至2014年368例(Ptrend=0.026)。
- 肺动静脉瘘患者中位年龄57.5岁,无肺动静脉瘘者72.5岁。
- 肺动静脉瘘患者年龄调整住院致残率39.6%,无肺动静脉瘘者46.9%;住院病死率1.8% vs 5.1%。
- 肺动静脉瘘患者与无肺动静脉瘘者静脉溶栓率相似(5.9% vs 5.8%),但未接受机械取栓(0% vs 0.7%)。
关键数值与推荐
- 肺动静脉瘘患者发生急性缺血性卒中的独立风险标志(OR[95%CI]):低氧血症8.4[6.3-11.2]、肺出血7.9[4.1-15.1]、肺高血压4.3[4.1-15.1]、卵圆孔未闭4.2[3.5-5.1]、鼻出血3.7[2.1-6.8]、静脉血栓2.6[1.9-3.6]、缺铁性贫血2[1.5-2.7]。
临床怎么用
- 对年轻缺血性卒中患者应筛查肺动静脉瘘及相关风险标志如低氧血症、缺铁性贫血。
- 肺动静脉瘘相关卒中患者可考虑静脉溶栓,但机械取栓应用需进一步评估。
局限性
- 回顾性研究基于行政数据库,可能存在编码偏倚和诊断准确性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Pulmonary arteriovenous fistulas (PAVFs) are a treatable cause of acute ischemic stroke (AIS), not mentioned in current American Heart/Stroke Association guidelines. PAVFs are recognized as an important complication of hereditary hemorrhagic telangiectasia. METHODS: The prevalence of PAVF and hereditary hemorrhagic telangiectasia among patients admitted with AIS in the United States (2005-2014) was retrospectively studied, utilizing the Nationwide Inpatient Sample database. Clinical factors, morbidity, mortality, and management were compared in AIS patients with and without PAVF/hereditary hemorrhagic telangiectasia. RESULTS: Of 4 271 910 patients admitted with AIS, 822 (0.02%) were diagnosed with PAVF. Among them, 106 of 822 (12.9%) were diagnosed with hereditary hemorrhagic telangiectasia. The prevalence of PAVF per million AIS admissions rose from 197 in 2005 to 368 in 2014 (Ptrend, 0.026). Patients with PAVF were younger than AIS patients without PAVF (median age, 57.5 versus 72.5 years), had lower age-adjusted inpatient morbidity (defined as any discharge other than home; 39.6% versus 46.9%), and had lower in-hospital case fatality rates (1.8% versus 5.1%). Multivariate analyses identified the following as independent risk markers (odds ratio [95% CI]) for AIS in patients with PAVF: hypoxemia (8.4 [6.3-11.2]), pulmonary hemorrhage (7.9 [4.1-15.1]), pulmonary hypertension (4.3 [4.1-15.1]), patent foramen ovale (4.2 [3.5-5.1]), epistaxis (3.7 [2.1-6.8]), venous thrombosis (2.6 [1.9-3.6]), and iron deficiency anemia (2 [1.5-2.7]). Patients with and without PAVF received intravenous thrombolytics at a similar rate (5.9% versus 5.8%), but those with PAVF did not receive mechanical thrombectomy (0% versus 0.7%). CONCLUSIONS: Pulmonary arteriovenous fistula-related ischemic stroke represents an important younger demographic with a unique set of stroke risk markers, including treatable conditions such as causal PAVFs and iron deficiency anemia.
引用
- Topiwala KK, Patel SD, Pervez M, et al. Ischemic Stroke in Patients With Pulmonary Arteriovenous Fistulas. Stroke. 2021. PMID: 34082575. doi:10.1161/STROKEAHA.120.032073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。